Pembrolizumab in combination with chemoradiotherapy is in clinical development for the
treatment of patients with high-risk, locally advanced cervical cancer. Cervical cancer arises
when abnormal cells lining the cervix begin to grow uncontrollably and create tumours. Cervical
cancer may not present symptoms, however the most common symptoms seen are unusual
vaginal bleeding, pain during sex, vaginal discharge and pain in the pelvis.
Pembrolizumab with chemoradiotherapy for treating high-risk locally advanced cervical cancer
Pembrolizumab in combination with chemoradiotherapy is in clinical development for the treatment of patients with high-risk, locally advanced cervical cancer.
Indications:
Cervical cancer
Therapeutic Areas:
Female Reproductive Cancer
Year:
2022